Metal and Metal Oxide Nanoparticle as a Novel Antibiotic Carrier for the Direct Delivery of Antibiotics

Kotrange, Harshada; Najda, Agnieszka; Bains, Aarti; Gruszecki, Robert; Chawla, Prince; Tosif, Mansuri M.

doi:10.3390/ijms22179596

Cited by 71 publications

(46 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biofabricated CuO-NPs have gained interest as an antibacterial therapy due to their unique morphologies, diameters, and biocompatibility. A type of CuO-NPs is antimicrobial, working against both Gram-positive and Gram-negative bacteria. , Previous studies have shown that the antibacterial property of CuO-NPs is produced through a green method utilizing the Tabernaemontana divaricata leaf extract and shown against Helicobacter pylori …”

Section: Resultsmentioning

confidence: 99%

In Vivo Analgesic, Anti-Inflammatory, and Anti-Diabetic Screening of Bacopa monnieri-Synthesized Copper Oxide Nanoparticles

et al. 2022

View full text Add to dashboard Cite

In this work, an ecofriendly approach for biogenic production of copper oxide nanoparticles (CuO-NPs) was proposed by utilizing the Bacopa monnieri leaf extract as a reducing and stabilizing agent. The synthesis of CuO-NPs was instantly confirmed by a shift in the color of the copper solution from blue to dark gray. The use of UV−visible spectroscopy revealed a strong narrow peak at 535 nm, confirming the existence of monoclinic-shaped nanoparticles. The average size of CuO-NPs was 34.4 nm, according to scanning electron microscopy and transmission electron microscopy studies. The pristine crystalline nature of CuO-NPs was confirmed by X-ray diffraction. The monoclinic form of CuO-NPs with a crystallite size of 22 nm was determined by the sharp narrow peaks corresponding to 273, 541, 698, 684, and 366 Bragg's planes at different 2θ values. The presence of different reducing metabolites on the surface of CuO was shown by Fourier transform infrared analysis. The biological efficacy of CuO-NPs was tested against Helicobacter felis, Helicobacter suis, Helicobacter salomonis. and Helicobacter bizzozeronii. H. suis was the most susceptible strain with an inhibition zone of 15.84 ± 0.89 mm at 5 mg/mL of NPs, while the most tolerant strain was H. bizzozeronii with a 13.11 ± 0.83 mm of inhibition zone. In in vivo analgesic activity, CuO-NPs showed superior efficiency compared to controls. The maximum latency time observed was 7.14 ± 0.12 s at a dose level of 400 mg/kg after 90 min, followed by 5.21 ± 0.29 s at 400 mg/kg after 60 min, demonstrating 65 and 61% of analgesia, respectively. Diclofenac sodium was used as a standard with a latency time of 8.6 ± 0.23 s. The results observed in the rat paw edema assays showed a significant inhibitory activity of the plant-mediated CuO-NPs. The percentage inhibition of edema was 74% after 48 h for the group treated with CuO-NPs compared to the control group treated with diclofenac (100 mg/kg) with 24% edema inhibition. The solution of CuO-NPs produced 82% inhibition of edema after 21 days when compared with that of the standard drug diclofenac (73%). CuO-NPs vividly lowered glucose levels in STZ-induced diabetic mice, according to our findings. Blood glucose levels were reduced by about 33.66 and 32.19% in CuO-NP and (CuO-NP + insulin) groups of mice, respectively. From the abovementioned calculations, we can easily conclude that B. monnieri-synthesized CuO-NPs will be a potential antibacterial, anti-diabetic, and anti-inflammatory agent on in vivo and in vitro basis.

show abstract

Section: Resultsmentioning

confidence: 99%

In Vivo Analgesic, Anti-Inflammatory, and Anti-Diabetic Screening of Bacopa monnieri-Synthesized Copper Oxide Nanoparticles

et al. 2022

View full text Add to dashboard Cite

show abstract

“…TiO 2 /ZnO nanoparticles have a more pronounced bactericidal effect against E. coli compared to ZnO nanoparticles, while Ag/TiO 2 /ZnO nanoparticles are more effective than TiO 2 /ZnO nanoparticles [ 132 ].…”

Section: Complex Inpsmentioning

confidence: 99%

“…However, INPs have significant potential not only as effective antibacterial components of drugs, but also as possible carriers of next-generation drugs providing targeted delivery and controlled release into diseased tissue. When studying the antibacterial properties of such hybrid systems of antibacterial drugs, it emerged that they are characterized not only by their expansion of the spectrum of action, but also by the mutual enhancement of the antibacterial activities of INPs and antibiotics [ 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 ].…”

Section: Concluding Remarks and Perspectivesmentioning

confidence: 99%

Nanoparticles of Bioactive Metals/Metal Oxides and Their Nanocomposites with Antibacterial Drugs for Biomedical Applications

et al. 2022

View full text Add to dashboard Cite

The increasing appearance of new strains of microorganisms resistant to the action of existing antibiotics is a modern problem that requires urgent decision. A promising potential solution is the use of nanoparticles of bioactive metals and their oxides as new antibacterial agents, since they are capable of affecting pathogenic microorganisms by mechanisms different from the mechanisms of action of antibiotics. Inorganic nanoparticles possess a wide spectrum of antibacterial activity. These particles can be easily conjugated with drug molecules and become carriers in targeted drug-delivery systems. This paper discusses the benefits and prospects of the application of nanoparticles from metals and metal oxides and their nanocomposites with antibacterial drugs.

show abstract

“…This is to reduce the loss of metal-containing NPs and NP amount and their activities in blood circulation besides minimizing damage to host cells and tissue [ 104 ]. Conjugation of existing antibiotics with highly targeted metal-containing NPs helps to selectively capture and kill MRSA by overloading defenses of drug-resistant bacteria [ 105 ]. A study from Wang and colleagues stated that target-oriented photo-functional NPs which are conjugated with both hematoporphyrin and monoclonal MRSA antibody killed selectively MRSA in L-929 cells [ 106 ].…”

Section: Challenges In Using Metal-containing Nps In Treating Mrsamentioning

confidence: 99%

A Metal-Containing NP Approach to Treat Methicillin-Resistant Staphylococcus aureus (MRSA): Prospects and Challenges

et al. 2022

View full text Add to dashboard Cite

Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of pneumonia in humans, and it is associated with high morbidity and mortality rates, especially in immunocompromised patients. Its high rate of multidrug resistance led to an exploration of novel antimicrobials. Metal nanoparticles have shown potent antibacterial activity, thus instigating their application in MRSA. This review summarizes current insights of Metal-Containing NPs in treating MRSA. This review also provides an in-depth appraisal of opportunities and challenges in utilizing metal-NPs to treat MRSA.

show abstract

Metal and Metal Oxide Nanoparticle as a Novel Antibiotic Carrier for the Direct Delivery of Antibiotics

Cited by 71 publications

References 90 publications

In Vivo Analgesic, Anti-Inflammatory, and Anti-Diabetic Screening of Bacopa monnieri-Synthesized Copper Oxide Nanoparticles

In Vivo Analgesic, Anti-Inflammatory, and Anti-Diabetic Screening of Bacopa monnieri-Synthesized Copper Oxide Nanoparticles

Nanoparticles of Bioactive Metals/Metal Oxides and Their Nanocomposites with Antibacterial Drugs for Biomedical Applications

A Metal-Containing NP Approach to Treat Methicillin-Resistant Staphylococcus aureus (MRSA): Prospects and Challenges

Contact Info

Product

Resources

About